ENTA
ENTA
NASDAQ · Biotechnology

Enanta Pharmaceuticals Inc

$11.00
+0.92 (+9.13%)
Financial Highlights (FY 2026)
Revenue
81.72M
Net Income
-102,436,812
Gross Margin
—
Profit Margin
-125.4%
Rev Growth
-8.8%
D/E Ratio
2.21
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — — 32.5% 32.5%
Operating Margin -130.6% -117.6% -22.0% -23.7%
Profit Margin -125.4% -119.1% -26.1% -23.5%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 81.72M 89.63M 75.01M 89.50M
Gross Profit — — 24.39M 29.10M
Operating Income -106,760,799 -105,390,719 -16,510,932 -21,235,526
Net Income -102,436,812 -101,122,223 -19,564,680 -21,049,434
Gross Margin — — 32.5% 32.5%
Operating Margin -130.6% -117.6% -22.0% -23.7%
Profit Margin -125.4% -119.1% -26.1% -23.5%
Rev Growth -8.8% -8.8% -3.9% +22.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 101.09M 101.09M 78.78M 74.71M
Total Equity 45.70M 45.70M 195.69M 201.77M
D/E Ratio 2.21 2.21 0.40 0.37
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -101,027,609 -105,271,721 -21,379,947 -25,062,209
Free Cash Flow — — -13,998,479 -22,107,180